Categories Analysis, Technology

Key takeaways from DocuSign’s (DOCU) Q4 2023 earnings report

In Q4, unadjusted profit benefited from higher interest income and income from other sources

DocuSign, Inc. (NASDAQ: DOCU), a leading provider of e-signature services, has been constantly increasing its market share by expanding the business into innovative areas like Contract Lifecycle Management. The digital signature market is estimated to grow to $48.4 billion by 2030 globally, representing a compound annual growth rate of 35.4%.

However, the macroeconomic challenges will be a hindrance to growth in the near term. Currently, DocuSign’s market capitalization is about $10.83 billion. The company’s top line grew by 14% to $659.6 million in the fourth quarter from $581 million a year earlier.  Earnings per share for the quarter was $0.02, compared to a loss of $0.15 per share in the year-ago fiscal quarter. Net income of $4.9 million benefited from higher interest income, and income from other sources. Adjusted EPS was $0.65, which is sharply higher than the $0.48 reported in the same period of the previous year.


Docusign Inc (DOCU) Q4 2023 Earnings Call Transcript


The contribution of Subscription revenue to the top line was 98% while Professional and Other revenues accounted for the remaining 2%. Fourth-quarter billings rose 10% to $739 million year-over-year. Together, cash, cash equivalents, restricted cash, and investments came in at $1.2 billion at the end of the quarter.

DocuSign Q4 2023 earnings infographic

In FY2023, the net loss widened to $0.49 per share on account of higher operating expenses – a 20% increase to 97.5 million. The management expects the current market headwinds to persist in the coming quarters. Adobe Inc. (NASDAQ: ADBE), DocuSign’s main rival that competes with the company for market share, will be reporting earnings this week.

Outlook

The management forecasts that total revenues would be between $639 million and $643 million in the first quarter of 2024 — subscription revenue in the range of $625 million to $629 million. Billings are expected to be in the range of $615 million to $625 million. For fiscal 2024, the company estimates revenue to be between $2.695 billion and $ 2.707 billion, while full-year billings are expected to be in the $2.705-$2.725 billion range.

What Next?

Though the stock created a big hype in the early phase of the pandemic lockdown – climbing to an all-time high in 2021 – it is currently trading a dismal 83% below that peak. There is a probability of further downfall this year if the financial performance is weak in the coming quarters.  

Last week, DOCU fell about 19% soon after the earnings release. At the moment, it is advisable to follow a watch-and-wait policy, for investing. However, the industry has upside potential, and it is likely to stabilize once the market gyrations get over in the next few months.

_________________________________________________________________________________________________________________

Stocks you may like:

Apple (AAPL) Stock

Microsoft (MSFT) Stock

Alphabet (GOOGL) Stock

International Business Machines Corp. (IBM) Stock

_________________________________________________________________________________________________________________

Most Popular

CVX Earnings: Chevron reports lower revenue and profit for Q1 2024

Energy exploration company Chevron Corporation (NYSE: CVX) announced first-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation was $5.50 billion or

ABBV Earnings: AbbVie reports lower adj. profit for Q1 2024; revenue edges up

Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Friday announced first-quarter 2024 financial results, reporting a decline in adjusted earnings and a modest rise in revenues. The company reported worldwide net

CL Earnings: Key quarterly highlights from Colgate-Palmolive’s Q1 2024 financial results

Colgate-Palmolive Company (NYSE: CL) reported first quarter 2024 earnings results today. Net sales increased 6.2% year-over-year to $5.06 billion. Organic sales increased 9.8%. Net income attributable to Colgate-Palmolive Company was

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top